Quantifying the Benefits and Harms of Interventions: Relative vs. Absolute Risk
|
|
- Bridget Sutton
- 5 years ago
- Views:
Transcription
1 JOURNAL CLUB LECTURE SERIES: Quantifying the Benefits and Harms of Interventions: Relative vs. Absolute Risk Tuesday, May 12 th, 2015 Anil N. Makam, MD MAS Oanh K. Nguyen, MD MAS Division of General Internal Medicine Division of Outcomes & Health Services Research UT Southwestern Medical Center
2 Overall Objective of JC Summarize an article for a resident and you ve taught them a new fact. Teach a resident to critically appraise the literature and you taught them to be a life learner! Disclaimer: You will NOT learn these skills by showing up to Journal Club without having read the article in advance. This takes ~60 minutes to do well, but something is better than nothing. Don t let perfect be the enemy of good.
3 Roadmap (this may change) Overview August: overview of research, funding, RQ, predictors, outcomes Study design series: September: RCT Part 1 October 7th: RCT Part 2 October 21st: RCT Part 3 November: RCT Part 4 December: Observational cohort studies part 1 January: Observational cohort studies part 2 February: Cancelled March: Observational cohort studies part 3 Interpretation of results: April: P-values and confidence intervals May: Absolute (ARR, NNT) vs relative risks (RR, OR)
4 Anatomy of interpreting a paper Authors & funding sources Research question Study design Study subjects and how they will be sampled Variables and how they will be measured Predictor Outcome Confounders Source of history Chief concern HPI Interpretation of findings and statistical analyses Conclusion: validity, inferences, take-home message Physical Exam/Labs/Imaging Assessment/Plan
5 Overall Objective To provide you a foundational understanding and skills needed to interpret and apply relative and absolute risk to critically appraise the literature AND to clinical practice (EBM) Please review previous lectures on
6
7 Rationale Any treatment involves tradeoffs Weigh benefits against risks/costs This decision can be difficult How big is this box? And this one? Benefit $$ Harm Treatment
8 Rationale Effect size estimated in studies can help us figure out the size of the boxes How big is this box? And this one? Benefit $$ Harm Treatment
9 Rationale: You will encounter this routinely How strongly should you discourage consumption of deli meats and soft cheese to prevent listeriosis? We will come back to this
10 Lecture Objectives Understand how to determine if an intervention is beneficial using effect size: Relative risk and relative risk reduction Absolute risk & number needed to treat (NNT) Basic calculation examples Examples applying lessons learned to patient care
11 Lecture Objectives Understand how to determine if an intervention is beneficial using effect size: Relative risk and relative risk reduction Absolute risk & number needed to treat (NNT) Basic calculation examples Examples applying lessons learned to patient care
12 Is the Intervention Beneficial? Studies compare an outcome in treated versus untreated persons Example: MI occurred in 10% in treated vs. 15% in untreated (P-value=0.03) P-values are used to decide if we should reject the null hypothesis and accept that the intervention is beneficial
13 Is the Intervention Beneficial? But p-values cannot help us interpret how beneficial (i.e. the effect size) Smaller the p-value does not mean more effective the intervention, and vice versa Statistical significance (p<.05) does not mean clinical significance, and vice versa
14 Quantifying the Benefit Effect size How do we summarize & communicate this? What is really important for clinicians and policymakers? Example: MI in 10% (tx) vs. 15% (ctrl) How would you summarize the effect size? What do we do with these two numbers? 14
15 Quantifying the Benefit Two possibilities for effect size: 10% / 15% = % - 10% = 5% Relative Risk (RR) Absolute Risk Reduction (ARR) 15
16 Quantifying the Benefit Relative risk as a measure of effect size Medium Big Small RR = 0.66 is this big or small? MI: 10% vs. 15% in 10 years Death: 50% vs. 75% in 3 years Basal Cell CA: 2% vs. 3% in lifetime RR is NOT the best measure of effect size
17 Neither are Odds Ratio Odds ratios are another measure of relative benefit/harm Same limitations for quantifying benefits/harms using RRs apply to ORs RR = events/total at risk OR = events/non-events ORs are always larger than RR, but if event rate<10%, it approximates RR
18 ORs are always larger than RRs Outcome Rate in Control Group For fixed relative risk, ORs will increase as outcome rate increases
19 Quantifying the Benefit Absolute risk reduction (ARR) is better ARR = Risk difference = Risk 2 Risk 1 RR ARR MI: 10% vs. 15% in 10 years.66??? Death: 50% vs. 75% in 3 years.66??? Basal Cell CA: 2% vs. 3% in lifetime.66???
20 Quantifying the Benefit Absolute risk reduction (ARR) is better ARR = Risk difference = Risk 2 Risk 1 RR ARR MI: 10% vs. 15% in 10 years.66 5% Death: 50% vs. 75% in 3 years.66 25% Basal Cell CA: 2% vs. 3% in lifetime.66 1%
21 What does the 34% difference mean?
22 Nimotop Ad Graph Risk(tx) = 61/278 = 22% Risk(ctrl) = 92/276 = 33% RR = 22%/33% =.66 ARR = 33% -22% = 11% What is 34%? Relative risk reduction (RRR) = 1 RR = =.34 or 34%
23 Quantifying the Benefit Relative risk reduction (RRR) is no better than relative risk (RR) RR RRR MI: 10% vs. 15% in 10 years.66 34% Death: 50% vs. 75% in 3 years.66 34% Basal Cell CA: 2% vs. 3% in lifetime.66 34% RRR is ALWAYS bigger than ARR
24 Quantifying the Benefit BEWARE of risk reduction language!!! Is this ARR or RRR? We reduced risk by 34% Risk was 34% lower can t tell can t tell
25 Quantifying the Benefit Another reason that ARR is better: Translate into number needed to treat NNT = 1/ARR
26 Why is NNT = 1/ARR? 100 SAH patients treated 67 no stroke anyway 11 strokes prevented R2 R1 22 strokes with Nimotop ARR = R2 R1 ARR = = strokes with no treatment 22 strokes with with treatment
27 Why is NNT = 1/ARR? Treat 100 SAH patients prevent 11 strokes Ratio manipulation: 100 treated 1 treated 9.1 treated = = 11 prevented.11 prevented 1 prevented 1/ARR = NNT
28 Quantifying the Benefit NNT is best expressed in a sentence: Need to treat 10 persons with SAH using nimodipine for 21 days to prevent 1 cerebral infarction
29 Lecture Objectives Understand how to determine if an intervention is beneficial using: Relative risk and relative risk reduction Absolute risk & number needed to treat (NNT) Basic calculation examples Examples applying lessons learned to patient care
30 Example 1 NNT calculation practice: RR ARR NNT MI: 10% vs. 15% in 10 years.66 5%??? Death: 50% vs. 75% in 1 year.66 25%??? Basal Cell CA: 2% vs. 3% in lifetime.66 1%???
31 Example 1 NNT calculation practice: Statins Chemo Sunscreen every day RR ARR NNT MI: 10% vs. 15% in 10 years.66 5% 20 Death: 50% vs. 75% in 1 year.66 25% 4 Basal Cell CA: 2% vs. 3% in lifetime.66 1% 100 NNT expression practice:
32 Example 1 NNT expression practice Need to treat 20 patients with statins for 10 years to prevent 1 MI Need to treat 4 patients with chemo for 1 year to prevent 1 death Need to treat 100 patients with sunscreen every day for their whole life to prevent 1 basal cell cancer
33 Example 2 Warfarin vs. placebo for atrial fibrillation Warfarin Placebo Risk of major bleed (/yr) 1.2% 0.7% What s the RR, ARI (absolute risk increase), and NNH? Ann Intern Med 1999; 131:
34 Example 2 Warfarin vs. placebo for atrial fibrillation RR = R1/R2 = 1.2% / 0.7% = 1.7 ARI = R1 R2 = 1.2% - 0.7% = 0.5% NNH = 1/ARI = 1/0.5% = 200 If you treat 200 afib patients with warfarin, you will cause 1 major bleed per year Ann Intern Med 1999; 131:
35 Lecture Objectives Understand how to determine if an intervention is beneficial using: Relative risk and relative risk reduction Absolute risk & number needed to treat (NNT) Basic calculation examples Examples applying lessons learned to patient care
36 Applying to Individual Patients Example 3: Warfarin vs. placebo for stroke prevention in atrial fibrillation RR = 0.34; RRR = 0.66 How do you estimate how beneficial prescribing warfarin is for an individual patient?
37 Applying to Individual Patients Example 3: Warfarin vs. placebo for stroke prevention in atrial fibrillation (RR = 0.34; RRR = 0.66) 1. Estimate Risk for Individual: Use CHA2DS-VASc Patient 1: CHA2DS2-VASc = 0 0.7% stroke risk/year without therapy Patient 2: CHA2DS2-VASc = 3 4.3% stroke risk/year without therapy Patient 3: CHA2DS2-VASc = % stroke risk/year without therapy
38 Applying to Individual Patients Example 3: Warfarin vs. placebo for stroke prevention in atrial fibrillation (RR = 0.34; RRR = 0.66) 2. Calculate NNT for an Individual Patient 1: CHA2DS2-VASc = 0 0.7% stroke risk/year without therapy ARR = 0.7% - (0.7%*.34) = 0.5%; NNT = 1/.005 = 200 Patient 2: CHA2DS2-VASc = 3 4.3% stroke risk/year without therapy ARR = 4.3% - (4.3%*.34) = 2.8%; NNT = 1/0.028 = 35 Patient 3: CHA2DS2-VASc = % stroke risk/year without therapy ARR =12.5% - (12.5%*.34) = 8.3%; NNT=1/0.083= 12
39 Applying to Individual Patients Example 3: NNT expression practice: Pt 1 with score of 0: NNT = 200 Need to treat 200 patients with CHA2DS2-VASc of 0 with warfarin each year to prevent 1 stroke (but 199 patients derive no benefit) Pt 2 with score of 3: NNT = 35 Need to treat 35 patients with CHA2DS2-VASc of 3 with warfarin each year to prevent 1 stroke (but 34 patients derive no benefit) Pt 3 with score of 6: NNT = 12 Need to treat 12 patients with CHA2DS2-VASc of 6 with warfarin each year to prevent 1 stroke (but 11 patients will derive no benefit)
40 Applying to Individual Patients What else do you need to know to decide whether to prescribe warfarin? Harms (NNH for bleeding) and costs (drug is cheap but monitoring is cumbersome) Value of stroke compared to major bleed and costs?
41 Applying to Individual Patients What s the value of the benefits and risks? How bad is 1 stroke compared to 1 bleed? Stroke prevention $$ Bleed Warfarin
42 Applying to Individual Patients What else do you need to know to decide whether to prescribe warfarin? Harms (NNH for bleeding) and costs (drug is cheap but monitoring is time intensive) Value of stroke compared to major bleed and costs? Decision analyses weight benefits and harms (Ex#4) Guidelines help to determine population thresholds Shared decision making to tailor based on individual tolerance of risks and benefits Best approach is to use pictogram decision aids
43 Pictogram showing the annual stroke risk of a patient with atrial fibrillation and a CHA2DS2-VASc score of 3. Luke Seaburg et al. Circulation. 2014;129: Copyright American Heart Association, Inc. All rights reserved.
44 Applying to Individual Patients: Example 4: Treating Diabetes in the elderly Relative risk reduction for treating diabetes: Visual loss: RRR = 29% per 0.9% in A1c Neuropathy: RRR = 19% per 0.9% in A1c Microalbuminuria: RRR = 33% per 0.9% in A1c UKPDS Group. Lancet 1998
45 Applying to Individual Patients: Treatment Scenario 1: Patient has A1c=8.5%, you prescribe metformin, A1c is reduced to 7.0% NNT NNT NNT Vijan, S. JAMA Int Med. 2014
46 Applying to Individual Patients: Treatment Scenario 2: Same patient as before, a1c to 8.5% after 10 years of metformin therapy, you prescribe insulin, a1c back to 7% NNT NNT NNT Vijan, S. JAMA Int Med. 2014
47 Applying to Individual Patients: Thou Shall Treat Level of Risk (AND not level of risk factor) Now when you consider disutility of taking metformin/insulin daily and harms of therapy:
48 Summary Points RR and p-values good for hypothesis testing and statistics (i.e., does it work?) Beware of ambiguous language w/ RR and RRR ARR and NNT (ARI and NNH) much better for interpreting clinical importance (i.e. should you prescribe it? Is it worth it?) ARR = risk difference between groups; NNT = 1/ARR Can be calculated at population or individual level
49 Take Home Points Thou shall treat level of risk, not level of risk factor SHALL NOT TREAT : SHALL TREAT BASED ON: LDL CV Risk, life expectancy A1c Microvascular risk, life expectancy BMD Prior fracture, FRAX score, life expectancy SBP/DBP CV Risk, life expectancy
50 Take Home Points Thou shall treat level of risk, not level of risk factor (LDL, A1c, BMD, SBP/DBP) Incorporate your patient s preferences into decision not everyone has same tolerance of risk and benefits HAVE THERAPEUTIC HUMILITY! For most interventions, over 90% (NNT 10), if not over 99% (NNT 100), of your patients will derive zero benefit (aside from placebo effect)
51 Risk of Listeriosis in Pregnancy 1 case in 83,000 servings of deli meat 1 case in 5 million servings of soft cheese Eat at your own risk Einarson, Can Fam Physician 2010
52 Acknowledgements Several slides borrowed from: Mark Pletcher, MD, MPH Associate Professor Departments of Epidemiology & Biostatistics and Medicine UCSF
53 @AnilMakam
54 Not sure Next Lecture
Outline. What is Evidence-Based Practice? EVIDENCE-BASED PRACTICE. What EBP is Not:
Evidence Based Practice Primer Outline Evidence Based Practice (EBP) EBP overview and process Formulating clinical questions (PICO) Searching for EB answers Trial design Critical appraisal Assessing the
More informationPresentation Outline. Introduction to Biomedical Research Designs. EBM: A Practical Definition. Grade the Evidence (Example McMaster Grading System)
Presentation Outline Introduction to Biomedical Research Designs Sean D. Sullivan, R.Ph., PhD Professor of Pharmacy, Public Health and Medicine University of Washington Why a course in Biomedical Research
More informationJournal Club: Fairfax Internal Medicine. Stephanie Shin PGY-2 Bianca Ummat PGY-2 July 27, 2012
Journal Club: Fairfax Internal Medicine Stephanie Shin PGY-2 Bianca Ummat PGY-2 July 27, 2012 S Objective Review EBM basic principles Learn how to apply the principles in critically appraising the article.
More informationEvidence Based Medicine
Course Goals Goals 1. Understand basic concepts of evidence based medicine (EBM) and how EBM facilitates optimal patient care. 2. Develop a basic understanding of how clinical research studies are designed
More informationCritical Appraisal of Evidence
Critical Appraisal of Evidence A Focus on Intervention/Treatment Studies Bernadette Mazurek Melnyk, PhD, CPNP/PMHNP, FNAP, FAAN Associate Vice President for Health Promotion University Chief Wellness Officer
More informationCLINICAL DECISION USING AN ARTICLE ABOUT TREATMENT JOSEFINA S. ISIDRO LAPENA MD, MFM, FPAFP PROFESSOR, UPCM
CLINICAL DECISION USING AN ARTICLE ABOUT TREATMENT JOSEFINA S. ISIDRO LAPENA MD, MFM, FPAFP PROFESSOR, UPCM Principles of Decision Making Knowing the patient s true state is often unnecessary Does my patient
More informationEBM: Therapy. Thunyarat Anothaisintawee, M.D., Ph.D. Department of Family Medicine, Ramathibodi Hospital, Mahidol University
EBM: Therapy Thunyarat Anothaisintawee, M.D., Ph.D. Department of Family Medicine, Ramathibodi Hospital, Mahidol University How to appraise therapy literature Are the result valid? What are the result?
More informationPreventing Cardiovascular Disease Stroke Primary Prevention Guidelines. John Potter Professor Ageing & Stroke Medicine University of East Anglia
Preventing Cardiovascular Disease Stroke Primary Prevention Guidelines John Potter Professor Ageing & Stroke Medicine University of East Anglia Preventing Cardiovascular Disease Stroke Primary Prevention
More informationCritical Appraisal. Dave Abbott Senior Medicines Information Pharmacist
Critical Appraisal Dave Abbott Senior Medicines Information Pharmacist Aims Identify key components of clinical trial design and apply these to a critical appraisal of the literature Be able to work out
More information8/18/10. Disclosure. Objectives. A Pervasive Concern. Evidence Based Medicine, Family Physicians, and Knowledge Translation (KATIE)
Evidence Based Medicine, Family Physicians, and Knowledge Translation (KATIE) David Gardner PharmD, MSc Michael Allen MD Dalhousie Refresher February 2010 Disclosure David Gardner Research/ Department
More informationCritical Appraisal of Evidence A Focus on Intervention/Treatment Studies
Critical Appraisal of Evidence A Focus on Intervention/Treatment Studies Bernadette Mazurek Melnyk, PhD, CPNP/PMHNP, FAANP, FAAN Associate Vice President for Health Promotion University Chief Wellness
More informationConsider the following hypothetical
Nurse Educator Nurse Educator Vol. 32, No. 1, pp. 16-20 Copyright! 2007 Wolters Kluwer Health Lippincott Williams & Wilkins How to Read, Interpret, and Understand Evidence-Based Literature Statistics Dorette
More informationFIRST DO NO HARM: AN EBM ODYSSEY. Cathleen Colón-Emeric, MD, MHS Geriatrics, Department of Medicine Durham VA GRECC
FIRST DO NO HARM: AN EBM ODYSSEY Cathleen Colón-Emeric, MD, MHS Geriatrics, Department of Medicine Durham VA GRECC colon001@mc.duke.edu 919 660-7517 Learning Objectives 1. Describe the types of studies
More informationJAMA. 2011;305(24): Nora A. Kalagi, MSc
JAMA. 2011;305(24):2556-2564 By Nora A. Kalagi, MSc Cardiovascular disease (CVD) is the number one cause of mortality and morbidity world wide Reducing high blood cholesterol which is a risk factor for
More informationGLOSSARY OF GENERAL TERMS
GLOSSARY OF GENERAL TERMS Absolute risk reduction Absolute risk reduction (ARR) is the difference between the event rate in the control group (CER) and the event rate in the treated group (EER). ARR =
More informationUpdate in the Literature 2012
Update in the Literature 2012 Mel L. Anderson, MD, FACP Chief, Hospital Medicine Section Associate Chief, Medical Service Denver VA Medical Center Associate Professor of Medicine University of Colorado
More informationPrevention: When Do Benefits Start and End? What Do They Have in Common?
Prevention: When Do Benefits Start and End? Providence Internal Medicine Spring Symposium April 14, 2016 Mari Kai, MD What Do They Have in Common? 82 year old female 62 year old male Estimated Life Expectancy
More informationTHERAPY WORKSHEET: page 1 of 2 adapted from Sackett 1996
THERAPY WORKSHEET: page 1 of 2 adapted from Sackett 1996 Citation: Are the results of this single preventive or therapeutic trial valid? Was the assignment of patients to treatments randomised? -and was
More informationCritical Appraisal of a Meta-Analysis: Rosiglitazone and CV Death. Debra Moy Faculty of Pharmacy University of Toronto
Critical Appraisal of a Meta-Analysis: Rosiglitazone and CV Death Debra Moy Faculty of Pharmacy University of Toronto Goal To provide practitioners with a systematic approach to evaluating a meta analysis
More informationDyslipidemia: Lots of Good Evidence, Less Good Interpretation.
Dyslipidemia: Lots of Good Evidence, Less Good Interpretation. G Michael Allan Evidence & CPD Program, ACFP Associate Professor, Dept of Family, U of A. CFPC CoI Templates: Slide 1 Faculty/Presenter Disclosure
More informationPrimary Prevention of Stroke
Primary Prevention of Stroke Dr Chris Ellis Cardiologist Green Lane CVS Service, Auckland City Hospital & Auckland Heart Group, Mercy Hospital, Auckland 67 Pages Long, 735 References 29 Sub-Headings for
More informationShould We Require Informed Consent Forms for Risk Factor Treatment?
Should We Require Informed Consent Forms for Risk Factor Treatment? John S. Yudkin Emeritus Professor of Medicine, University College London Outline The nature of informed consent for prescribing Treatment
More informationPGY1 Learning activities-ebcp Scripts
PGY1 Learning activities-ebcp Scripts Interns will meet in small groups, once per month, to discuss EBCP scripts designed to promote understanding of basic EBCP concepts. EBCP scripts (see example below)
More informationJournal Club Critical Appraisal Worksheets. Dr David Walbridge
Journal Club Critical Appraisal Worksheets Dr David Walbridge The Four Part Question The purpose of a structured EBM question is: To be directly relevant to the clinical situation or problem To express
More informationKathryn M. Rexrode, MD, MPH. Assistant Professor. Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School
Update: Hormones and Cardiovascular Disease in Women Kathryn M. Rexrode, MD, MPH Assistant Professor Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School Overview Review
More informationProviding High Value Cost-Conscious Care:
Providing High Value Cost-Conscious Care: Biostatistical Concepts You Need to Know 2012-2013 Presentation #5 0f 10 http://hvc.acponline.org/ Learning Objectives Understand that a working knowledge of basic
More informationHARM. Definition modified from the IHI definition of Harm by the QUEST Harm Workgroup
Indonesia Clinical epidemiology and Evidence Based Medicine (ICE(ICE-EBM) HARM Jarir At Thobari (FK UGM) Efficacious Medical intervention Harm HARM Unintended physical injury resulting from or contributed
More informationHow to Make Sense of Statistics Reported in the Medical Literature
How to Make Sense of Statistics Reported in the Medical Literature Colin P. West, MD, PhD Division of General Internal Medicine Division of Biomedical Statistics and Informatics Denise M. Dupras, MD, PhD
More informationBiostatistics 2 - Correlation and Risk
BROUGHT TO YOU BY Biostatistics 2 - Correlation and Risk Developed by Pfizer January 2018 This learning module is intended for UK healthcare professionals only. PP-GEP-GBR-0957 Date of preparation Jan
More informationBranko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center
Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center THE END! CHANGABLE Blood pressure Diabetes Mellitus Hyperlipidemia Atrial fibrillation Nicotine Drug abuse Life style NOT CHANGABLE
More informationA DECISION AID FOR AFIB STROKE PREVENTION FOR PATIENTS WITH ATRIAL FIBRILLATION
A DECISION AID FOR AFIB STROKE PREVENTION FOR PATIENTS WITH ATRIAL FIBRILLATION For Patients with VERY HIGH RISK You have atrial fibrillation, also known as AFib, which means you have an irregular heart
More informationIntro to Evidence Based Medicine
Intro to Evidence Based Medicine Dr Hasan Nugud Consultant Paediatric Surgeon 4/18/2015 EBM Resources 1 Outline What is EBM? Why do we need it? How to use EBM in daily practice The five steps Formulating
More informationHypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic
Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered
More information9/4/2013. Decision Errors. Hypothesis Testing. Conflicts of Interest. Descriptive statistics: Numerical methods Measures of Central Tendency
Conflicts of Interest I have no conflict of interest to disclose Biostatistics Kevin M. Sowinski, Pharm.D., FCCP Pharmacotherapy Webinar Review Course Tuesday, September 3, 2013 Descriptive statistics:
More informationPolypharmacy, Medication Nihilism, and the art of de-prescribing
Polypharmacy, Medication Nihilism, and the art of de-prescribing Temple Family Practice Review Course Leon S. Kraybill, MD, CMD Geriatrics, Lancaster General Hospital Physicians Division Chief, LGH Division
More informationWhy is Earlier and More Aggressive Treatment of T2 Diabetes Better?
Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:
More informationHypertension Guidelines: Lessons for Primary Care. Paul A James MD Professor and Chair Department of Family Medicine University of Washington
Hypertension Guidelines: Lessons for Primary Care Paul A James MD Professor and Chair Department of Family Medicine University of Washington Disclaimer and Financial Disclosure I have no financial interests
More informationLearning Objectives 9/9/2013. Hypothesis Testing. Conflicts of Interest. Descriptive statistics: Numerical methods Measures of Central Tendency
Conflicts of Interest I have no conflict of interest to disclose Biostatistics Kevin M. Sowinski, Pharm.D., FCCP Last-Chance Ambulatory Care Webinar Thursday, September 5, 2013 Learning Objectives For
More informationIntroduzione al metodo GRADE
Introduzione al metodo GRADE Atto Billio MD, MSc EBHC Ematologia e TMO-Bolzano Gruppo linee guida SIE Critique of EBM De-emphasizes patient values Doesn t account for individual variation Devalues clinical
More informationHow to CRITICALLY APPRAISE
How to CRITICALLY APPRAISE an RCT in 10 minutes James McCormack BSc(Pharm), Pharm D Professor Faculty of Pharmaceutical Sciences, UBC Vancouver, BC, Canada medicationmythbusters.com CRITICAL APPRAISAL
More informationA DECISION AID FOR AFIB STROKE PREVENTION FOR PATIENTS WITH ATRIAL FIBRILLATION
A DECISION AID FOR AFIB STROKE PREVENTION FOR PATIENTS WITH ATRIAL FIBRILLATION For Patients with HIGH RISK You have atrial fibrillation, also known as AFib, which means you have an irregular heart beat.
More informationThe who, what, why, where, and when of Clinical Practice Guidelines (CPGs)
The who, what, why, where, and when of Clinical Practice Guidelines (CPGs) Appraisal of Guidelines for Research and Evaluation (AGREE) II DOMAIN 1. SCOPE AND PURPOSE DOMAIN 2. STAKEHOLDER INVOLVEMENT DOMAIN
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationSEX LIES CHOLESTEROL
SEX LIES and the CHOLESTEROL What You Don t Know Could Hurt You! TRUTH about Cardiovascular Disease Statistics Estimates for the year 2006 are that 81,100,000 people in the United States have one or more
More informationEpidemiology and Prevention of Stroke
Copyright Information Copyright protected material has been deleted from this presentation. References to the deleted material are provided for each slide. Epidemiology and Prevention of Stroke Larry B.
More informationDual Antiplatelet Therapy Made Practical
Dual Antiplatelet Therapy Made Practical David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management Clinical Associate Professor
More informationIs a Mediterranean diet best for preventing heart disease?
Is a Mediterranean diet best for preventing heart disease? By Peter Attia, M.D. This week an article titled Primary Prevention of Cardiovascular Disease with a Mediterranean Diet was featured in the New
More information15.301/310, Managerial Psychology Prof. Dan Ariely Recitation 8: T test and ANOVA
15.301/310, Managerial Psychology Prof. Dan Ariely Recitation 8: T test and ANOVA Statistics does all kinds of stuff to describe data Talk about baseball, other useful stuff We can calculate the probability.
More informationInitiating Insulin in Primary Care for Type 2 Diabetes Mellitus. Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre
Initiating Insulin in Primary Care for Type 2 Diabetes Mellitus Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre Outline How big is the problem? Natural progression of type 2 diabetes What
More informationEssential Skills for Evidence-based Practice: Statistics for Therapy Questions
Essential Skills for Evidence-based Practice: Statistics for Therapy Questions Jeanne Grace Corresponding author: J. Grace E-mail: Jeanne_Grace@urmc.rochester.edu Jeanne Grace RN PhD Emeritus Clinical
More informationTRIPLE THERAPY, NOACs with concurrent indication for DAPT. Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust
TRIPLE THERAPY, NOACs with concurrent indication for DAPT Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust Content Why consider triple therapy What we know of triple therapy Current
More informationDisclosures No relationships (not even to an employer) No off-label uses. Cholesterol Lowering Guidelines: What now?
Disclosures No relationships (not even to an employer) No off-label uses Cholesterol Lowering Guidelines: What now?, FACP 1 2 65-year-old white woman Total cholesterol 175mg/dL HDL 54 mg/dl LDL 96 mg/dl
More informationCalculating RR, ARR, NNT
Calculating RR, ARR, NNT In a trial RR = Event rate (eg # of people with one stroke/ total people) in treatment group/event rate in the control group. ARR = Event rate in control group minus the event
More informationModifiable Up-Stream Risk Factors:
Modifiable Up-Stream Risk Factors: Recent Studies in AF Prevention Behzad Pavri, MD, FACC, FHRS Professor of Medicine Director, CCEP Fellowship Thomas Jefferson University Hospital, Philadelphia, USA Disclosures
More informationEpidemiologic study designs
Epidemiologic study designs and critical appraisal of scientific papers Rolf H.H. Groenwold, MD, PhD Bio sketch MD, PhD in epidemiology Associate professor of Epidemiology at UMC Utrecht Research focus
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationobservational studies Descriptive studies
form one stage within this broader sequence, which begins with laboratory studies using animal models, thence to human testing: Phase I: The new drug or treatment is tested in a small group of people for
More informationIs it worth offering cardiovascular disease prevention to the elderly? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany
Is it worth offering cardiovascular disease prevention to the elderly? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany Is it worth offering cardiovascular disease prevention to the elderly?
More informationNew Math: Taking on Overdiagnosis Waste and Harm Flipped Classroom: Pre-work
New Math: Taking on Overdiagnosis Waste and Harm Flipped Classroom: Pre-work IHI Forum, Session C24 Faculty: Dr. James Leo, Helen Macfie Session Objectives Understand the difference between absolute and
More informationHowever, if instead, CHD risk is plotted on a doubling scale (as in slide 2) then there is a
Slides 1 and 2: These two illustrative slides (based on notionaldata) were used in my presentation to Dr Godlee at our meeting on 2 December 2013 to show that, if the risk of coronary disease (CHD) is
More informationA Guidance Statement from the American College of Physicians
Hemoglobin A1c Targets for Glycemic Control with Pharmacologic Therapy in Non-Pregnant Adults with Type 2 Diabetes Mellitus: A Guidance Statement from the American College of Physicians Timothy J. Wilt,
More informationDr. Engle has received an unrestricted educational grant for the MD Anderson Pain Medicine Fellowship.
Mitchell Engle, MD, PhD Dr. Mitchell Engle earned his medical degree and a Ph.D. in Pharmacology from the University Of Iowa Carver College Of Medicine. His Ph.D. research examined the role of the spinal
More informationTop 5 (Topics) Papers In GIM Rocky Mountain ACP Internal Medicine Meeting Raj Padwal November 13, 2008
Top 5 (Topics) Papers In GIM 2008 Rocky Mountain ACP Internal Medicine Meeting Raj Padwal November 13, 2008 Methods Searched ACPJC/EBM, TOC of top medical journals, MEDSCAPE Best Evidence, consultation
More informationW e have previously described the disease impact
606 THEORY AND METHODS Impact numbers: measures of risk factor impact on the whole population from case-control and cohort studies R F Heller, A J Dobson, J Attia, J Page... See end of article for authors
More informationProf. Fiorenzo Gaita
Adavances in Cardiac Arrhythmias and Great Innovations in Cardiology Turin 2014 Can rhythm control strategy reduce the risk of clinical and silent cerebral ischemia? Prof. Fiorenzo Gaita Director of the
More informationUpdates in Therapeutics 2015: The Pharmacotherapy Preparatory Review & Recertification Course
Updates in Therapeutics 2015: The Pharmacotherapy Preparatory Review & Recertification Course Study Designs: Fundamentals and Interpretation Kevin M. Sowinski, Pharm.D., FCCP Purdue University, College
More informationDr Julia Hopyan Stroke Neurologist Sunnybrook Health Sciences Centre
Dr Julia Hopyan Stroke Neurologist Sunnybrook Health Sciences Centre Objectives To learn what s new in stroke care 2010-11 1) Acute stroke management Carotid artery stenting versus surgery for symptomatic
More informationMaking comparisons. Previous sessions looked at how to describe a single group of subjects However, we are often interested in comparing two groups
Making comparisons Previous sessions looked at how to describe a single group of subjects However, we are often interested in comparing two groups Data can be interpreted using the following fundamental
More informationAtrial Fibrillation Detection in the Community and Hospital settings
Atrial Fibrillation Detection in the Community and Hospital settings Shuja Punekar Consultant Cerebrovascular Physician Hon Senior Lecturer, Manchester Medical School How common is AF in the population
More informationAtrial Fibrillation Implementation challenges. Lesley Edgar Ross Maconachie
Atrial Fibrillation Implementation challenges Lesley Edgar Ross Maconachie Atrial Fibrillation Most common heart rhythm disturbance Rapid and irregular electrical signals Reduced efficiency of blood flow
More informationEvidence and So Much More
Evidence and So Much More James McCormack, BSc(Pharm), PharmD Professor, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC Entire salary comes through the UBC Faculty of
More informationHealth Studies 315. Clinical Epidemiology: Evidence of Risk and Harm
Health Studies 315 Clinical Epidemiology: Evidence of Risk and Harm 1 Patients encounter (possibly) risky exposures Alcohol during pregnancy (fetal risk) Electromagnetic fields (cancer risk) Vasectomy
More informationIs Lower Better for LDL or is there a Sweet Spot
Is Lower Better for LDL or is there a Sweet Spot ALAN S BROWN MD, FACC FNLA FAHA FASPC DIRECTOR, DIVISION OF CARDIOLOGY ADVOCATE LUTHERAN GENERAL HOSPITAL, PARK RIDGE, ILLINOIS DIRECTOR OF CARDIOLOGY,
More informationHypertension Management Controversies in the Elderly Patient
Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No
More informationSteven Jubelirer, MD Clinical Professor Medicine WVU Charleston Division Senior Research Scientist CAMC Research Institute
Steven Jubelirer, MD Clinical Professor Medicine WVU Charleston Division Senior Research Scientist CAMC Research Institute Objectives Develop a systematic way to think about benefits and harms of cancer
More informationClinical Controversies in Perioperative Medicine
Clinical Controversies in Perioperative Medicine Hugo Quinny Cheng, MD Division of Hospital Medicine University of California, San Francisco Predicting & Managing Cardiac Risk A 70-y.o. man with progressive
More informationThe Flozins Quest for Clarity?
The Flozins Quest for Clarity? Choosing Wisely with Academic Detailing 2018 ARE THEY THE REAL DEAL Disclosure statements The Academic Detailing Service is operated by Dalhousie Continuing Professional
More informationA Primer on Health Economics & Integrating Findings from Clinical Trials into Health Technology Assessments and Decision Making
Presenter: Chris Cameron CANNeCTIN November 8, 2013 A Primer on Health Economics & Integrating Findings from Clinical Trials into Health Technology Assessments and Decision Making Acknowledgements Vanier
More informationDual Antiplatelet duration in ACS: too long or too short?
Dual Antiplatelet duration in ACS: too long or too short? Leonardo Bolognese, MD, FESC, FACC Cardiovascular Department, Arezzo, Italy Paradigm Shift the ideal duration of DAPT: a moving target Early (stent-related)
More informationNew options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital
New options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital Disclosures: Honoraria, research support, and consulting f Sanofi, Boehringer-Ingleheim, Portola, BMS, Bayer,
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
PREVENTING CARDIOVASCULAR DISEASE IN WOMEN: Current Guidelines for Hypertension, Lipids and Aspirin Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationRisk Study. Section for Clinical Epidemiology and Biostatistics. Definition
Risk Study Section for Clinical Epidemiology and Biostatistics What is Risk? Definition The probability of some untoward event The likelihood that people who are exposed to certain factors (risk factors)
More informationClinical Controversies in Perioperative Medicine
Clinical Controversies in Perioperative Medicine Hugo Quinny Cheng, MD Division of Hospital Medicine University of California, San Francisco Cardiac Evaluation: New Guidelines A 70-y.o. man with progressive
More informationDiabetes Mellitus: Implications of New Clinical Trials and New Medications
Diabetes Mellitus: Implications of New Clinical Trials and New Medications Estimates of Diagnosed Diabetes in Adults, 2005 Alka M. Kanaya, MD Asst. Professor of Medicine UCSF, Primary Care CME October
More informationExpressions and illustra0ons of treatment effect. Ka$e Program Dalhousie University
Expressions and illustra0ons of treatment effect Ka$e Program Dalhousie University The following slides demonstrate how data from clinical trials can be expressed. Slides provide insights regarding how
More informationIs There An Association?
Is There An Association? Exposure (Risk Factor) Outcome Exposures Risk factors Preventive measures Management strategy Independent variables Outcomes Dependent variable Disease occurrence Lack of exercise
More informationPrimary Prevention of Cardiovascular Disease (CVD) Events with Statins. 1 Primary Prevention of Cardiovascular Disease (CVD) Events with Statins
Primary Prevention of Cardiovascular Disease (CVD) Events with Statins 1 Primary Prevention of Cardiovascular Disease (CVD) Events with Statins 2 Welcome by Michael Pignone, MD, MPH Hi, my name is Dr.
More informationEvidence Based Medicine
Hamadan University of medical sciences School of Public Health Department of Epidemiology Evidence Based Medicine Amin Doosti-Irani, PhD in Epidemiology 10 March 2017 a_doostiirani@yahoo.com 1 Outlines
More informationInterdependence of Evidence-based Practice & Shared Decision Making Implications for Quality
New York Academy of Medicine August 6, 2015 Interdependence of Evidence-based Practice & Shared Decision Making Implications for Quality Henry H. Ting, MD, MBA Senior Vice President & Chief Quality Officer,
More informationNovel PCSK9 Outcomes. in Perspective: Lessons from FOURIER & ODYSSEY LDL-C. ASCVD Risk. Suboptimal Statin Therapy
LDL-C Novel PCSK9 Outcomes Suboptimal Statin Therapy ASCVD Risk in Perspective: Lessons from FOURIER & ODYSSEY Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine Director,
More informationMMS/Mass Coalition Program, Nov. 4, 2008 Patients with AF: Who Should be on Warfarin?
MMS/Mass Coalition Program, Nov. 4, 2008 Patients with AF: Who Should be on Warfarin? Daniel E. Singer, MD Massachusetts General Hospital Harvard Medical School 1 Speaker Disclosure Information DISCLOSURE
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #326 (NQF 1525): Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY
More informationPreventive Cardiology Scientific evidence
Preventive Cardiology Scientific evidence Professor David A Wood Garfield Weston Professor of Cardiovascular Medicine International Centre for Circulatory Health Imperial College London Primary prevention
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationEvaluating Effectiveness of Treatments. Elenore Judy B. Uy, M.D.
Evaluating Effectiveness of Treatments Elenore Judy B. Uy, M.D. OUTLINE 1. Why evaluate effectiveness 2. How to acquire evidence 3. How to appraise evidence Directness Validity Results 4. Our Case WALA
More informationThe patient with multiple chronic conditions: balancing guidelines and patient preference
The patient with multiple chronic conditions: balancing guidelines and patient preference Sid Feldman MD CCFP FCFP Associate Professor, Department of Family and Community Medicine, University of Toronto
More informationGlossary of Practical Epidemiology Concepts
Glossary of Practical Epidemiology Concepts - 2009 Adapted from the McMaster EBCP Workshop 2003, McMaster University, Hamilton, Ont. Note that open access to the much of the materials used in the Epi-546
More informationClinical and Economic Value of Rivaroxaban in Coronary Artery Disease
CHRISTOPHER B. GRANGER, MD Professor of Medicine Division of Cardiology, Department of Medicine; Director, Cardiac Care Unit Duke University Medical Center, Durham, NC Clinical and Economic Value of Rivaroxaban
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Warfarin and the risk of major bleeding events in patients with atrial fibrillation: a population-based study Laurent Azoulay PhD 1,2, Sophie Dell Aniello MSc 1, Teresa
More information